A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study toEvaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding,anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type1 Dia

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Dia
StatusActive
Effective start/end date6/1/195/31/24

Funding

  • PROVENTION BIO, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.